200 related articles for article (PubMed ID: 34827546)
1. Is Aducanumab for LMICs? Promises and Challenges.
Gunawardena IPC; Retinasamy T; Shaikh MF
Brain Sci; 2021 Nov; 11(11):. PubMed ID: 34827546
[TBL] [Abstract][Full Text] [Related]
2. Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey.
DiStefano MJ; Alexander GC; Polsky D; Anderson GF
J Am Geriatr Soc; 2022 Jun; 70(6):1685-1694. PubMed ID: 35129210
[TBL] [Abstract][Full Text] [Related]
3. Making the Case for Accelerated Withdrawal of Aducanumab.
Whitehouse P; Gandy S; Saini V; George DR; Larson EB; Alexander GC; Avorn J; Brownlee S; Camp C; Chertkow H; Fugh-Berman A; Howard R; Kesselheim A; Langa KM; Perry G; Richard E; Schneider L
J Alzheimers Dis; 2022; 87(3):1003-1007. PubMed ID: 35404287
[TBL] [Abstract][Full Text] [Related]
4. Physician Perspectives on the Food and Drug Administration's Decision to Grant Accelerated Approval to Aducanumab for Alzheimer's Disease.
Dhruva SS; Kesselheim AS; Woloshin S; Ji RZ; Lu Z; Darrow JJ; Redberg RF
Clin Pharmacol Ther; 2023 Sep; 114(3):614-617. PubMed ID: 37218658
[TBL] [Abstract][Full Text] [Related]
5. Is Aducanumab treatment developed to prevent progression of Alzheimer's disease cost-effective in Turkey?
Yigit V; Kalender S; Cetinturk I
Cost Eff Resour Alloc; 2023 Aug; 21(1):51. PubMed ID: 37559042
[TBL] [Abstract][Full Text] [Related]
6. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
Vaz M; Silva V; Monteiro C; Silvestre S
Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
[TBL] [Abstract][Full Text] [Related]
7. Lessons Learned from Approval of Aducanumab for Alzheimer's Disease.
Heidebrink JL; Paulson HL
Annu Rev Med; 2024 Jan; 75():99-111. PubMed ID: 38285515
[TBL] [Abstract][Full Text] [Related]
8. Conventional Versus New Treatment: Comparing the Effects of Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonist With Aducanumab.
Chin E; Jaqua E; Safaeipour M; Ladue T
Cureus; 2022 Nov; 14(11):e31065. PubMed ID: 36475205
[TBL] [Abstract][Full Text] [Related]
9. Aducanumab-Hope or Disappointment for Alzheimer's Disease.
Wojtunik-Kulesza K; Rudkowska M; Orzeł-Sajdłowska A
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901797
[TBL] [Abstract][Full Text] [Related]
10. Practical Considerations in the Administration of Aducanumab for the Neurologist.
Coerver K; Yu MM; D'Abreu A; Wasserman M; Nair KV
Neurol Clin Pract; 2022 Apr; 12(2):169-175. PubMed ID: 35733944
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.
Ross EL; Weinberg MS; Arnold SE
JAMA Neurol; 2022 May; 79(5):478-487. PubMed ID: 35344024
[TBL] [Abstract][Full Text] [Related]
12. Aducanumab for the treatment of Alzheimer's disease: a systematic review.
Rahman A; Hossen MA; Chowdhury MFI; Bari S; Tamanna N; Sultana SS; Haque SN; Al Masud A; Saif-Ur-Rahman KM
Psychogeriatrics; 2023 May; 23(3):512-522. PubMed ID: 36775284
[TBL] [Abstract][Full Text] [Related]
13. A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease.
Mukhopadhyay S; Banerjee D
J Alzheimers Dis; 2021; 83(4):1537-1552. PubMed ID: 34366359
[TBL] [Abstract][Full Text] [Related]
14. An insider's perspective on FDA approval of aducanumab.
Wang Y
Alzheimers Dement (N Y); 2023; 9(2):e12382. PubMed ID: 37215506
[TBL] [Abstract][Full Text] [Related]
15. Aducanumab: evidence from clinical trial data and controversies.
Tampi RR; Forester BP; Agronin M
Drugs Context; 2021; 10():. PubMed ID: 34650610
[TBL] [Abstract][Full Text] [Related]
16. Aducanumab for Alzheimer's Disease: Summarized Data From EMERGE, ENGAGE, and PRIME Studies.
Yuksel JM; Noviasky J; Britton S
Sr Care Pharm; 2022 Aug; 37(8):329-334. PubMed ID: 35879846
[No Abstract] [Full Text] [Related]
17. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
Budd Haeberlein S; Aisen PS; Barkhof F; Chalkias S; Chen T; Cohen S; Dent G; Hansson O; Harrison K; von Hehn C; Iwatsubo T; Mallinckrodt C; Mummery CJ; Muralidharan KK; Nestorov I; Nisenbaum L; Rajagovindan R; Skordos L; Tian Y; van Dyck CH; Vellas B; Wu S; Zhu Y; Sandrock A
J Prev Alzheimers Dis; 2022; 9(2):197-210. PubMed ID: 35542991
[TBL] [Abstract][Full Text] [Related]
18. Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease.
Herring WL; Gould IG; Fillit H; Lindgren P; Forrestal F; Thompson R; Pemberton-Ross P
Neurol Ther; 2021 Dec; 10(2):919-940. PubMed ID: 34426940
[TBL] [Abstract][Full Text] [Related]
19. Aducanumab in Alzheimer's disease: A critical update.
Ashique S; Sirohi E; Kumar S; Rihan M; Mishra N; Bhatt S; Gautam RK; Singh SK; Gupta G; Chellappan DK; Dua K
Curr Med Chem; 2023 Jul; ():. PubMed ID: 37497712
[TBL] [Abstract][Full Text] [Related]
20. Aducanumab as a Novel Treatment for Alzheimer's Disease: A Decade of Hope, Controversies, and the Future.
Esang M; Gupta M
Cureus; 2021 Aug; 13(8):e17591. PubMed ID: 34646644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
